Robust, Consistent Phase 3 Data and Real-World Evidence Outcomes Support ANX005 as Potential First Targeted Therapy for GBS; Pre-BLA Meeting ...

Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory ...

Our novel scientific approach focuses on C1q, the initiating molecule of classical complement’s potent inflammatory pathway that when misdirected can lead to tissue damage and loss. By targeting ...

Q4 2024 Earnings Call Transcript February 28, 2025 Gem Hopkins: Good morning and good afternoon, everyone. Thank you for ...

Lake Como, an enchanting lakeside retreat just 45 minutes from Milan, offers a tranquil contrast to the city’s hustle. This ...

Undergraduate students also have the option of completing a minor, which can complement their major or enable them ... and provided community outreach through their Pathways Program. Her students have ...

About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.

The complement cascade is a biochemical process in the blood that helps or 'complements' cells of the immune system to eliminate invading pathogens. When activated by one of three pathways ...

The Victorian era saw a proliferation of classical music organisations, beginning with the Philharmonic Society, 1813, and the Royal Academy of Music, 1822, both keenly promoting Beethoven's music.